Study: Diabetes Drug Metformin Mimics Exercise-Related Molecule in Prostate Cancer Patients

A study has found that the diabetes medication metformin increases blood levels of a molecule associated with the metabolic effects of exercise in men with prostate cancer. The research suggests this could be relevant for patients whose ability to exercise is limited by treatment side effects.

Study Details and Key Finding

The research was conducted by physician-scientists at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. The findings were published in the journal EMBO Molecular Medicine.

The study focused on the molecule N-lactoyl-phenylalanine (Lac-Phe). This molecule is naturally produced in the body under metabolic demand, such as during intense physical exercise, and has been linked in prior research to shifts in energy use and appetite regulation.

The key finding was that prostate cancer patients taking metformin showed elevated levels of Lac-Phe in their blood. These levels were reported to be comparable to those observed in individuals after strenuous exercise, and the effect was seen even in the absence of physical activity.

Context for Prostate Cancer Treatment

The research was conducted in the context of prostate cancer care. A common treatment for prostate cancer is hormone-based therapy, which can disrupt a patient's metabolism. Potential side effects of these therapies include weight gain, insulin resistance, and increased cardiovascular risk.

While exercise is a recommended strategy to help manage these metabolic side effects, many cancer patients face barriers to physical activity due to treatment-related fatigue, pain, or advanced disease.

Research Observations and Implications

The study reported several specific observations:

• The increase in Lac-Phe levels in patients taking metformin persisted even after they began hormone therapy.
• The elevated Lac-Phe levels were not correlated with anti-tumor responses, such as changes in prostate-specific antigen (PSA) levels.
• Instead, researchers noted that Lac-Phe levels appeared to reflect the body's management of energy, weight, and metabolic stress during treatment.
• Similar increases in Lac-Phe were also observed in patients on other metabolic therapies, suggesting it may be a broader indicator of metabolic response.

The research indicates that metformin likely influences metabolic health through multiple biological pathways, with Lac-Phe being one significant component. The findings contribute to the understanding of how metformin, a widely used medication, might support metabolic health in prostate cancer patients alongside standard cancer treatments.